MapLight Therapeutics (MPLT) Other Operating Expenses (2024 - 2025)

MapLight Therapeutics (MPLT) reported Other Operating Expenses of -$177.0 million for Q4 2025, down 376.64% on a YoY basis from $64.0 million in Q4 2024, and down 376.64% sequentially from $64.0 million in Q4 2024.

MapLight Therapeutics (MPLT) Other Operating Expenses (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Other Operating Expenses data on file, last reported at -$177.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 376.64% year-over-year to -$177.0 million; the trailing twelve-month figure through Dec 2025 stood at -$113.0 million (changed N/A YoY), and the FY2025 full-year result was -$177.0 million, changed N/A from the prior year.
  • Other Operating Expenses eased to -$177.0 million in Q4 2025, from $64.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $64.0 million in Q4 2024 to a low of -$177.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 MapLight Therapeutics 305.82 Mn 305.82 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -177.01 Mn
Dec 31, 2024 63.99 Mn